Background. This study compared the risk of fatal cerebrovascular accidents (CVAs) in patients with early-stage glottic laryngeal cancer receiving surgery or external beam radiation therapy (EBRT). Methods. Using a competing risks survival analysis, we compared the risk of death because of CVA among patients with early-stage glottic laryngeal cancer receiving surgery or EBRT in the Surveillance, Epidemiology, and End Results (SEER) database. Results. The cumulative incidence of fatal CVA at 15 years was higher in patients receiving EBRT (2.8%; 95% confidence interval [CI], 2.3% to 3.4%) compared to surgery (1.5%; 95% CI, 0.8% to 2.3%; p 5 .024). In multivariable competing risks regression models, EBRT remained associated with an increased risk of fatal CVA compared to surgery (adjusted hazard ratio [HR], 1.75; 95% CI, 1.04-2.96; p 5 .037). Conclusion. Treatment for early-stage glottic laryngeal cancer with EBRT was associated with a small increase in the risk of late fatal CVA events relative to surgery.
INTRODUCTION
Optimal treatment for early-stage glottic laryngeal cancer provides high rates of tumor control, larynx preservation, and minimal morbidity. Standard treatment with radiotherapy, transoral laser microsurgery, or open partial laryngectomy is associated with excellent local control rates of 85% to 95%. [1] [2] [3] External beam radiation therapy (EBRT) is acutely well tolerated in most patients, and reports of severe treatment-related complications are uncommon. 1, 4 However, the highly curable nature of this disease underscores the importance of studying long-term treatment-related morbidity and mortality.
A growing body of evidence has suggested that receipt of head and neck EBRT may be associated with increased risk of vascular stenosis and subsequent cerebrovascular accident (CVA). [5] [6] [7] However, previous studies have not explored long-term cerebrovascular outcomes in the early stage patient population or have been limited by small sample size. Early-stage glottic laryngeal cancer is unique among head and neck cancers in that definitive radiation therapy does not include elective treatment of the cervical lymph nodes, resulting in more limited radiation exposure to the carotid artery. Conventional EBRT consists of opposed lateral fields and does not typically consider or address radiation dose to the carotid arteries. Although alternative treatment techniques, such as the use of angled treatment fields or intensity-modulated radiation therapy, allow for reduction of carotid dose when compared with conventional treatment techniques, their role in routine clinical care remains controversial because of concerns that more conformal treatment may compromise excellent local control rates. [8] [9] [10] CVA-related outcomes in patients with early-stage glottic laryngeal cancer receiving EBRT are of particular interest because of excellent disease prognosis and existing alternatives to conventional EBRT (ie, surgery or carotid-sparing radiation techniques). Therefore, we conducted a retrospective observational cohort study to compare the incidence of fatal CVAs in patients with earlystage glottic laryngeal cancer who received either surgery or EBRT.
MATERIALS AND METHODS

Data source
This study used registry data from the Surveillance, Epidemiology, and End Results (SEER) database. The SEER program is a national cancer registry that collects information regarding incident cancer cases in registries that comprise approximately 26% of the U.S. population.
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The SEER program includes data regarding patients of all ages with cancer, in contrast to the linked SEER-Medicare database, which is largely limited to older adult patients 65 years of age. 12 This study was approved by the Institutional Review Board of the University of Pennsylvania.
Study cohort
Eligible patients included individuals diagnosed with pathologically confirmed squamous cell carcinoma of the glottic larynx diagnosed between January 1, 1983, and December 31, 2008. Supplementary Figure 1 (online only) illustrates definition of the study cohort and the reasons for exclusion. We limited our study population to patients with stage I disease. We identified 7237 patients undergoing EBRT and 1484 patients undergoing surgery as initial management. Patients receiving both surgery and EBRT were excluded from this study.
Definition of variables
The primary endpoint of this study was death from CVA. Cause of death is recorded for each individual followed longitudinally in the SEER database from death certificates, and is specified based upon International Classification of Diseases coding (versions 8-10).
Receipt of surgical or radiation treatment was assigned based on treatment coding in SEER, which records the first course of cancer-directed therapy initiated within 1 year of diagnosis. Surgical techniques are further specified in SEER and include local excision, laser surgery, and partial or total laryngectomy.
Patient characteristics included age at diagnosis, sex, race, ethnicity, and marital status. We staged patients according to the American Joint Commission on Cancer Staging Manual 7th edition from disease extent variables in SEER. 13 Demographic characteristics included diagnosis year, SEER registry, and county or metropolitan area population. We used county level median household income as a proxy for individual socioeconomic status, because individual-level socioeconomic data are not available in SEER.
Statistical analysis
We compared patient characteristics by treatment using chi-square statistics for categorical variables and t tests for continuous variables. We analyzed survival and cumulative incidence of fatal CVAs by treatment using a competing risks approach to account for the potential influence of death from other causes on the incidence of fatal CVA. Competing risks data analysis may be used to estimate the cumulative incidence of a specific event of interest when there are multiple potential dependent events of interest or competing outcomes. Under these conditions, a Kaplan-Meier approach may overestimate cumulative incidence because it censors competing risk events and assumes that all events are independent of one another.
14-16 Therefore, we considered non-CVA-related deaths to be competing risk events when estimating cumulative incidence functions of fatal CVA by treatment.
We compared cumulative incidence functions using k-sample test statistics, as described by Gray. 17 In order to adjust for potential confounders, we used multivariable competing risks regression models to compare the risk of death because of CVA after treatment with surgery or EBRT. 18 Covariates were selected based on clinical significance in prior studies or significance in univariate analysis. These included age, sex, race, marital status, county or metropolitan area population, and median household income. We performed tests of interaction to examine potential effect modification of age and year of diagnosis on the association of treatment with fatal CVA.
We determined the number needed to harm from the inverse of attributable risk and report confidence intervals (CIs) based on the Wilson score method. 19 The number needed to harm may be interpreted as the average number of individuals receiving EBRT that will result in 1 excess fatal CVA compared to surgery at 15 years. As multivariable adjustment did not substantially attenuate the unadjusted estimate of the effect of radiotherapy on fatal CVA, we calculated the attributable risk of CVA associated with EBRT by subtracting the 15-year cumulative incidence of fatal CVAs among patients receiving surgery from those receiving EBRT. 20 We undertook a sensitivity analysis to further investigate patients' baseline risk of vascular disease in which we compared the risk of death because of heart disease among the 2 treatment groups in a multivariable competing risks regression framework. Because EBRT in this setting does not result in radiation exposure to the heart, we expected no association between receipt of EBRT and death because of heart disease. Because baseline risk factors for heart disease and CVA are similar, this analysis served to further examine baseline risk of vascular disease in the 2 treatment groups.
Statistical analysis was performed using Stata version 12 (College Station, TX), and R version 2.7.2 (Vienna, Austria). Statistical significance was set at 0.05 and all tests were 2-tailed.
RESULTS
Patient characteristics
The median follow-up time for the study population was 5.3 years (interquartile range, 2.4-9.4 years). Characteristics of patients receiving surgery (n 5 1484) and EBRT (n 5 7237) are described in Table 1 . The 2 treatment groups were similar with respect to patient and demographic characteristics. There was a statistically significant difference between the treatment groups in mean age (EBRT, 65.3 years; surgery, 64.5 years; p 5 .01) and race.
Competing risks analysis of death from cerebrovascular accident by treatment
Accounting for competing risks, the unadjusted cumulative incidence of fatal CVA at 5, 10, and 15 years was 1.0% (95% CI, 0.8% to 1.3%), 2.0% (95% CI, 1.6% to 2.4%) and 2.8% (95% CI, 2.3% to 3.4%), respectively, in the EBRT group, and 0.6% (95% CI, 0.2% to 1.0%), 1.4% (95% CI, 0.7% to 2.1%), and 1.5% (95% CI, 0.8% to 2.3%), respectively, in the surgery group ( Figure 1 ) and 60.4% (95% CI, 56.7% to 64.2%) in patients receiving surgery. In unadjusted competing risks regression models, EBRT was associated with a significantly increased risk of fatal CVA compared to surgery (hazard ratio [HR], 1.72; 95% CI, 1.02-2.89; p 5 .04). In multivariable competing risks regression models adjusted for patient and demographic characteristics, EBRT remained associated with an increased risk of fatal CVA compared to surgery (adjusted HR, 1.75; 95% CI, 1.04-2.96; p 5 .04; Table 3 ). Older age was also associated with an increased risk of CVA (year-on-year adjusted HR, 1.07; 95% CI, 1.06-1.09; p < .0001).
We also tested for interactions between age and treatment, as well as year of diagnosis and treatment on the occurrence of fatal CVA. Neither interaction term was statistically significant (p 5 .85 and p 5 .48, respectively).
Number needed to harm
The attributable risk of fatal CVA associated with exposure to EBRT was 1.3% at 15 years, resulting in a number needed to harm of 77 (95% CI, 50-100). In other words, on average, the treatment of 77 patients with early-stage laryngeal cancer with EBRT would result in 1 excess fatal CVA compared to surgery at 15 years.
Competing risks analysis of death from heart disease by treatment
As a sensitivity analysis, we also compared the risk of death because of heart disease by treatment. Accounting for competing risks, the unadjusted 15-year cumulative incidence of death because of heart disease was 14.8% (95% CI, 12.4% to 17.3%) in patients receiving surgery and 14.3% (95% CI, 13.2% to 15.5%) in patients receiving EBRT (p 5 .45; Figure 2 ). In multivariable competing risks regression models, EBRT was not associated with an increased risk of death because of heart disease (adjusted HR, 0.912; 95% CI, 0.77-1.09; p 5 .3; Table 3 ).
Overall survival
There was no significant difference in overall survival between the treatment groups in either unadjusted analyses (data not shown) or in multivariable Cox proportional hazards models (HR, 1.03; 95% CI, 0.95-1.13; Table 3 ).
DISCUSSION
We undertook this study to compare the risk of fatal CVA in patients with early-stage glottic laryngeal cancer who received either surgery or EBRT. Among patients in the SEER database, we found that treatment with EBRT Abbreviations: EBRT, external beam radiation therapy; IQR, interquartile range.
*Number suppressed because of Surveillance, Epidemiology, and End Results (SEER) confidentiality restrictions (cell size <11).
Data are presented as number of patients (%). Abbreviations: CI, confidence interval; CVA, cerebrovascular accident; EBRT, external beam radiation therapy.
Note: All cumulative incidence estimates shown are accounting for competing risks.
was associated with a small increase in the risk of late fatal CVA events when compared to surgery. Our results are consistent with and extend previously published studies reporting the association of head and neck EBRT with subsequent risk of CVA. A prior analysis of older patients with head and neck cancer using SEER-Medicare data noted an increased risk of CVA events associated with receipt of EBRT compared to surgery (HR, 1.50; 95% CI, 1.18-1.90; p 5 .0009). 5 However, the study did not report outcomes for patients diagnosed with primary laryngeal cancers and was limited to patients >65 years of age. Another retrospective cohort study from the Netherlands estimated the risk of CVA from a sample of patients receiving EBRT alone for laryngeal and parotid malignancies. 6 The authors compared the observed incidence of CVA in the study cohort with an expected CVA incidence rate from a geographically distant stroke registry and reported an increased relative risk (RR) of CVA (RR, 5.6; 95% CI, 3.1-9.4) among patients receiving EBRT in the study. In contrast, our study made use of a large sample of patients treated for early stage glottic laryngeal cancer with and without exposure to EBRT, in order to examine the association of EBRT with the long-term risk of subsequent fatal CVA.
Stroke-related outcomes in patients with early-stage glottic laryngeal cancer are of interest for several reasons. First, standard EBRT techniques for early-stage glottic laryngeal cancer target the primary tumor and omit elective treatment of the neck because of the very low risk of lymph node involvement. Consequently, a much shorter segment of the carotid artery receives radiation dose during EBRT when compared to other patients with head and neck cancer requiring elective nodal treatment. In nonradiated individuals, vascular atherosclerosis most commonly occurs within 2 cm of the common carotid artery bifurcation, which lies immediately adjacent to the glottic larynx. 21 Our study findings suggest that even quite limited radiation exposure of the carotid arteries in this region significantly increases the subsequent risk of death because of CVA. Abbreviations: HR, hazard ratio; CI, confidence interval; CVA, cerebrovascular accident; EBRT, external beam radiation therapy.
Competing risks regression model adjusted for: age at diagnosis, sex, median household income, race, ethnicity, marital status, year of diagnosis, and population of county of residence. Second, several studies have investigated the use of advanced EBRT treatment techniques for patients with early-stage glottic laryngeal cancer to allow for carotid artery dose reduction. 8, 9 Such techniques remain controversial because of concerns that more conformal EBRT may increase disease recurrence rates secondary to organ motion and contouring errors. 9, 10 Furthermore, there is no data currently available to inform estimates of dose response and a probable dose threshold for carotid injury. The results from our study underscore the potential importance of careful radiation therapy (RT) treatment planning and consideration of carotid dose reduction with the goal of reducing long-term treatment-related morbidity and mortality. Future studies should continue to investigate the use of conformal radiotherapy techniques in this setting to evaluate its safety and the potential reduction of treatment-related toxicity, such as CVA.
Third, advances in minimally invasive surgery, such as the development of endoscopic laser microsurgery, have allowed for high rates of local control as well as preservation of voice quality comparable to EBRT in patients with well-defined glottic carcinomas. 2, 22, 23 Such techniques may allow for reduced treatment-related morbidity in selected patients. Future evaluations of treatmentrelated morbidity remain critical to answer questions of comparative effectiveness.
Finally, consensus guidelines recommend screening for asymptomatic carotid artery stenosis in patients with a carotid bruit, known atherosclerosis, or at least 2 of the following risk factors for CVA: hypertension, hyperlipidemia, tobacco use, and family history of CVA. 24 EBRT is associated with a similar risk of CVA events compared to other established CVA risk factors (RR range, 1.4-3.2); however, EBRT is not currently addressed in published screening recommendations. 25 Furthermore, although there is growing evidence that head and neck EBRT is associated with an elevated risk of carotid stenosis, effective management strategies are not well established. 26, 27 Medical management of CVA risk factors may include the use of antiplatelet, anticoagulation, antihypertensive, or lipidlowering agents. However, additional studies are needed to evaluate the efficacy of such agents in preventing radiation-associated vascular disease. Although small studies suggest that carotid endarterectomy and carotid angioplasty with stenting are feasible in previously radiated patients, further investigation is needed to evaluate the efficacy of these procedures in such patients compared to medical management alone. [28] [29] [30] [31] [32] Our study has several limitations. First, as with any observational study, residual bias may remain even after adjusting for measured confounders. 33 For example, our study lacks information regarding diabetes, tobacco use, or other diagnosed comorbidities that are associated with the risk of CVA. To address this, we conducted multivariable competing risks survival analyses and also compared the risk of non-CVA-related mortality by treatment. We found no significant differences observed between the treatment groups with respect to overall survival or death because of other causes. We also examined fatal heart disease because the underlying risk factors for CVA and heart disease are similar. We found no association between treatment and death because of heart disease, which suggests that unmeasured differences in baseline risk of vascular disease between the 2 patient groups would not explain our primary finding of an association of EBRT with CVA.
Second, prior studies have compared the reliability of death certificates relative to secondary expert review of medical records and report positive predictive values of 59% to 96% in suspected cases of CVA. [34] [35] [36] While measurement error is a concern when using administrative data sets, these errors are likely to be nondifferential between the treatment groups. Nondifferential errors in sensitivity or specificity would bias observed study results toward the null hypothesis. 35 Therefore, our estimates of fatal CVA in this study are conservative.
Third, SEER only records fatal CVA, rather than other nonfatal CVA events. Approximately 20% of all CVA events are acutely fatal; therefore, our study likely underestimates the total CVA-related disease burden in this study population. 37 Fourth, our study cannot compare or adjust for local control rates between the treatment groups as this data is not available in SEER. However, expected local control rates would be high in both treatment groups. Finally, the data available in SEER do not specify RT details with respect to technique or dose delivered. However, RT techniques for early-stage glottic laryngeal cancer have changed only minimally during the past few decades, with the exception of the very recent interest in the use of intensity-modulated radiation therapy.
In conclusion, we found that treatment of early stage glottic laryngeal cancer with EBRT was associated with a small increase in the risk of late fatal CVA events relative to surgery. These results suggest the need for attention to carotid dose reduction through advanced conformal radiation treatment techniques, for further evaluation of modern surgical techniques, and for consideration of CVA prevention recommendations in patients receiving EBRT.
